Entelechon and Syntezza forge partnership for the Israeli market
The cooperation emphasizes the relevance of the Israeli market for European companies. Says Dr. Werner Deininger, Managing Director of Entelechon: "We are very proud to have found such an experienced partner in Syntezza. They will give us much more immediate access to our Israeli customers. Israel is a very exciting and dynamic environment for biotech developments."
Initially, gene synthesis and DNA analytics will be in the focus of the new partnership. However, looking farther into the future, both companies have even more ambitious plans: Entelechon as a provider of integrated solutions in synthetic biology aims at establishing contact with innovative research groups in Israel. Together with Syntezza, the company intends to start complex development projects in Israel, supported by currently developed solutions in the areas of protein engineering, metabolic modelling, and quantitative proteomics.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.